Acute exacerbations of chronic obstructive pulmonary disease

Emergency Medicine Clinics of North America

Volumn 21, Issue 2, 2003, Pages 331-352

  Palm, Kenneth H ^a   Decker, Wyatt W ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CEPHALOSPORIN DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; HELIOX; HYPNOTIC AGENT; IPRATROPIUM BROMIDE; ISOETARINE; LEVOFLOXACIN; METHYLPREDNISOLONE; METHYLXANTHINE; ORCIPRENALINE; PIRBUTEROL; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALBUTAMOL; TERBUTALINE; TIATROPIUM BROMIDE; TRANQUILIZER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; AIR POLLUTION; ANTIBIOTIC THERAPY; BLOOD GAS ANALYSIS; BRONCHODILATATION; CHRONIC BRONCHITIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY MONITORING; EMPHYSEMA; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPOKALEMIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MEDICAL NEBULIZER; METERED DOSE INHALER; NAUSEA; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SPUTUM ANALYSIS; TACHYCARDIA; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREMOR; VOMITING; XEROSTOMIA;

EID: 0038103724     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8627(03)00014-2     Document Type: Article

References (141)

1. Parshall M. Adult emergency visits for chronic cardiorespiratory disease: does dyspnea matter? Nurs Res 1999;48:62-72.
2. Singh G, Mathews T, Clarke S, et al. Annual summary of births, marriages, divorces and deaths: United States, 1994. Monthly Vital Statistics 1994;43.
3. Higgins M. Chronic airways disease in the United States: trends and determinants. Chest 1989;96:328S-34S.
4. Bailey W, Ferguson G, Higgins M, et al. The National Lung Health Education Program Executive Committee: Strategies in preserving lung health and preventing COPD and associated diseases. Chest 1998;113:123S-63S.
5. Department of Commerce. Statistical abstract of the United States 1997. Washington, DC: US Department of Commerce, Bureau of the Census; 1997.
6. Agency for Health Care Research and Policy. Healthcare cost and utilization project: nationwide inpatient sample for 1997 Available at: www.ahcpr.gov/data/hcup/hcupnet.htm. 1997.
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: definitions, epidemiology, pathophysiology, diagnosis and staging. Am J Respir Crit Care Med 1995;152:S78-83.
8. Honig E, Ingram R Jr., et al. Chronic bronchitis, emphysema, and airways obstruction. In: Harrison, editor. Principles of internal medicine. 14th edition. NewYork: McGrawHill; 1998:1453-60.
9. Snider G. Chronic obstructive pulmonary disease - a continuing challenge. Am Rev Respir Dis 1986;133:942-4.
10. Beck G, Doyle C, Schachter E. Smoking and lung function. Am Rev Respir Dis 1981; 123:149-55.
11. Burrows B. Predictors of loss of lung function and mortality in obstructive lung disease. Eur Respir Rev 1991;1:340-5.
12. Anthonisen N, Manfreda J, Warren C, et al. Antibiotic therapy of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
13. Burrows B, Knudson R, Camilli A, et al. The "hourse-racing effect" and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 1987;135:788-93.
14. Postma D. When can an exacerbation of COPD be treated at home? Lancet 1998; 351:1827-8.
15. Grossman R. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD. Chest 1998;113(Suppl):249-55.
16. US Surgeon General. The health consequences of smoking: chronic obstructive lung disease. US Department of Health and Human Research; 1984.
17. Niewoehner D, Kleinerman J, Rice D. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974;291:755-8.
18. Reynolds H. Bronchoalveolar lavage. Am Rev Respir Dis 1987;135:250-63.
19. Cantin A, Crystal R. Oxidants, antioxidants and the pathogenesis of emphysema. Eur J Respir Dis 1985;66:7-17.
20. Hossain S, Heard B. Hyperplasia of bronchial muscle in chronic bronchitis. J Pathol 1970;101:171-84.
21. Gil J, Weibel E. Extracellular lining of bronchioles after perfusion-fixation of rat lungs for electron microscopy. Anat Rec 1971;169:185-200.
22. Mooren H, Kramps J, Meijer C, et al. Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung. Thorax 1983;38:180-3.
23. Macklem P, Proctor D, Hogg J. The stability of peripheral airways. Respir Physiol 1970;8:191-203.
24. Gillooly M, Lamb D. Microscopic emphysema in relation to age and smoking habit. Thorax 1993;48:491-5.
25. Lamb D, McClean A, Gillooly M, et al. Relation between distal airspace size, bronchiolar attachment and lung function. Thorax 1993;48:1012-7.
26. Reid L, Melb M. Pathology of chronic bronchitis. Lancet 1954;1:275-8.
27. Jeffrey P. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129-36.
28. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;8:1333-8.
29. 1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-5.
30. Bhowmik A, Seemungal T, Sapsford R, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
31. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
32. Roland M, Bhowmik A, Sapsford R, et al. Sputum and plasma endothelin-1 levels in exacerbation of chronic obstructive pulmonary disease. Thorax 2001;56:30-5.
33. Gompertz S, O'Brian C, Bayley D, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2002;17:1112-9.
34. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
35. Redington A, Springall D, Ghatei M, et al. Endothelin in bronchoalveolar lavage fluid and its relation to airflow obstruction in asthma. Am J Respir Crit Care Med 1995;151:1034-9.
36. Dekhuijzen P, Aben K, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:813-6.
37. Pratico D, Basili S, Vieri M, et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F(2α)-III, an index of oxidant stress. Am J Respir Crit Care Med 1998;158:1709-14.
38. Montuschi P, Corradi M, Ciabattoni G, et al. Breath condensate analysis of 8-isoprostane: a new approach for assessment of oxidative stress in patients with chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med 1999;159(Suppl):A798.
39. Barnes P, Karin M. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
40. Cydulka R, Khandelwal S, Chronic obstructive pulmonary disease. In: Tintinalli J, Kelen G, Stapczynski J, editors. Emergency medicine - a comprehensive study guide, 5th edition. New York: McGraw-Hill; 485-90.
41. Irwin R, Caorrao W. A true exacerbation of chronic obstructive bronchitis can be objectively defined. Am Rev Respir Dis 1981;123(Suppl):151.
42. Seth S. Infectious etiology of acute exacerbation of chronic bronchitis. Chest 2000; 117(Suppl):380S-5S.
43. Gump D, Phillips C, Forsyth B, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976;113:465-74.
44. Beaty C, Grayston J, Wang S, et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;144:1408-10.
45. Buscho L, Saxtan D, Schultz P. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978;137:377-83.
46. Smith C, Golden C, Kanner R, et al. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1980;121:225-32.
47. Seemungal T, Haper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbation and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23.
48. Monso E, Ruiz J, Rosell A. Bacterial infection in chronic obstructive pulmonary disease (a study of stable and exacerbated outpatients using the protected specimen brush). Am J Respir Crit Care Med 1995;152:1316-20.
49. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
50. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. Am J Respir Crit Care Med 1994;150:648-55.
51. Donaldson G, Seemungal T, Jeffries D, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur J Respir Dis 1999;13:844-9.
52. Connors A, Dawson N, Thomas C, et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment). Am J Respir Crit Care Med 1996;14:959-67.
53. Seemungal T, Donaldson G, Paul E, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-22.
54. Thompson A, Tschler H, Rennard S. Pathogenesis, evaluation and therapy for massive hemoptysis. Clin Chest Med 1992;13:69-82.
55. Bohadona A. Breath sounds in the clinical assessment of airflow obstruction. Thorax 1978;33:345.
56. Cohen C, Zagelbaum G, Gross D, et al. Clinical manifestations of inspiratory muscle fatigue. Am J Med 1982;73:308.
57. Gilbert R, Ashutosh K, Auchmcloss J Jr, et al. Prospective study on controlled oxygen breathing. Chest 1977;71:456-62.
58. Hannhart B, Michalski H, Delorme N, et al. Reliability of six pulse oximeters in chronic obstructive pulmonary disease. Chest 1991;99:842-6.
59. Kelly A, McAlpine R, Kyle E. How accurate are pulse oximeters in patients with acute exacerbations of chronic obstructive airways disease? Respir Med 2001;95:336-40.
60. McCrory D, Brown C, Gelfand S, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119:1190-209.
61. Hoo G, Hakimian N, Santiago S. Hypercapnic respiratory failure in COPD patients: response to therapy. Chest 2000;117:169-77.
62. 2 and pH can be used to screen for significant hypercarbia in emergency patients with acute respiratory diseases. J Emerg Med 2002;22:15-9.
63. Emerman C, Cydulka R. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993;22:680-4.
64. Sherman S, Skoney J, Ravikrishnan K. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 1989;149:2493-6.
65. Tsai T, Gallagher E, Lombardi G, et al. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993;22:1854-8.
66. Emerman C, Connors A, Lukens T, et al. Relationship between arterial blood gases and spirometry in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1989;18:523-7.
67. American Thoracic Society. Statement: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152(Suppl):77-121.
68. Robert G, Subramanian N. Significance of cardiac arrhythmias during acute exacerbation of COPD. Chest 2000:118:193S-4S.
69. Lode H, Schaberg R, Raffenberg M, et al. Diagnostic problems in lower respiratory tract infection. J Antimicrob Chemother 1993;32:29-37.
70. Stockley R, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbation of COPD. Chest 2000;117:1638-45.
71. Bedon G, Block A, Wilmot C. The "28%" Venturi mask in obstructive airway disease. Arch Intern Med 1970;125:106-13.
72. Bone R, Pierce A, Johnson R. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease. Am J Med 1978;65:896-902.
73. Eldridge F, Gherman C. Studies of oxygen administration in respiratory failure. Ann Intern Med 1968;68:569-78.
74. Warrell D, Edwards R, Godfrey S, et al. Effect of controlled oxygen therapy on arterial blood gases in acute respiratory failure. BMJ 1970;2:452-5.
75. 2 on ventilation and blood gases in patients with chronic obstructive disease during acute respiratory failure. Rev Respir Dis 1980;122:747-54.
76. Stradling J. Hypercapnia during oxygen therapy in airways obstruction: a reappraisal. Thorax 1986;41:897-902.
77. Schmidt G, Hall J. Acute on chronic respiratory failure: assessment and management of patients with COPD in the emergent setting. JAMA 1989;261:3444-53.
78. Shrestha M, O'Brien T, Haddox R, et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Ann Emerg Med 1991;120:1206-9.
79. Emerman C, Cydulka R. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997; 29:474-8.
80. Karpel J, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbation of COPD. Chest 1990;98:835-9.
81. Rebuck A, Chapman K, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987;82:59-64.
82. Taylor D, Wilkins G, Herbison G, et al. Interaction between corticosteroid and βagonist drugs, biochemical and cardiovascular effects in normal subjects. Chest 1992;102:519-24.
83. Ahrens R, Smith G. Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 1984;4:105-21.
84. Turner M, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction - a meta-analysis. Arch Intern Med 1997;157:1736-44.
85. Siefkin A. Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease. Am J Med 1996;100:54-61.
86. Jasper A, Moshenifar Z, Kahan S, et al. Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987;91:614-8.
87. Wanner A. Clinical aspects of mucociliary transport. Am Rev Respir Dis 1977;116:73-125.
88. Dowell A, Heyman A, Sieker H, et al. Effect of aminophylline on respiratory center sensitivity in Cheyne-Stokes respiration and in pulmonary emphysema. N Engl J Med 1965;273:1447-53.
89. Matthay R, Berger H, Davies R, et al. Improvement in cardiac performance by oral long-acting theophylline in chronic obstructive pulmonary disease. Am Heart J 1982;104:1022-6.
90. Murciano D. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;311:349-53.
91. Foxworth J, Reisz G, Knudson S, et al. Theophylline and diaphragmatic contractility. Am Rev Respir Dis 1988;138:1532-4.
92. Cochrane Database of Systematic Reviews. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. 2001.
93. Rice K, Leatherman J, Duane P, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease: a controlled trial. Ann Intern Med 1987;107:305-9.
94. Emerman C, Devlin C, Connors A. Risk of toxicity in patients with elevated theophylline levels. Ann Emerg Med 1990;19:643-8.
95. Balter M, Hyland R, Low D, et al. Recommendations on the management of chronic bronchitis. Can Med Assoc J 1994;151:8-23.
96. Murphy T, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:1067-83.
97. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995;273:957-60.
98. Jorgensen J, Doern G, Maher L, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
99. Doern G. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99:3S-7S.
100. Grossman R, Mukerjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998;113:131-41.
101. Destache C, Dewan N, O'Donohue W, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43:107-13.
102. Masterson R, Burley C. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. International Journal of Antimicrobial Agents 2001;18:503-12.
103. McCarty J, Pierce P. Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis. Ann Asthma Immunol 2001;87:327-34.
104. Albert R, Martin T, Lewis S. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980;92:753-8.
105. Bullard M, Liaw S, Tsai Y, et al. Early corticosteroid use in acute exacerbation of chronic airflow obstruction. Am J Emerg Med 1996;14:139-43.
106. Emerman C, Connors A, Lukens T, et al. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989;95:563-7.
107. Thompson W, Nielson C, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
108. Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999;354:456-60.
109. Niewoehner D, Erbland M, Deupress R. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
110. Rostom R, Mink S, Hebert P, et al. The long-term efficacy of methylprednisolone in the treatment of acute exacerbation of COPD. Chest 1994;105(Suppl):161s.
111. Hirsch S, Viernes P, Kory R. The expectorant effect of glyceryl guaiacolate in patients with chronic bronchitis. Chest 1973;63:9-14.
112. Buist A, Sexton G, Nagy J, et al. The effect of smoking cessation and modication on lung function. Am Rev Respir Dis 1976;114:115-22.
113. Camilli A, Burrows B, Knudson R, et al. Longitudinal changes in forced expiratory volume in one second in adults. Am Rev Respir Dis 1989;135:794-9.
114. The Agency for Health Care Policy and Research. Clinical practice guidelines. JAMA 1996;275:1270-80.
115. Hughes J, Goldstern M, Shiffman S. Recent advances in pharmacotherapy of smoking cessation. JAMA 1999;281:72-6.
116. Vitacca M, Clini E, Pagani M, et al. Physiologic effects of early administered mask PAV (proportional assist ventilation) in patients with chronic obstructive pulmonary disease and acute respiratory failure. Crit Care Med 2000;28:1791-7.
117. Guerin C, Girard R, Chemorin C, et al. Facial mask noninvasive mechanical ventilation reduces the incidence of nosocomial pneumonia. A prospective epidemiological survey from a single ICU. Intensive Care Med 1997;23:1024-32.
118. Fagon J, Chastre J, Hance A, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-7.
119. Kramer B. Ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1999:130:1027-8.
120. Nouridine K, Combes P, Carton MJ, Beuret P, Cannamela A, Ducreux JC. Does noninvasive ventilation reduce the ICU nosocomial infection risk? A prospective clinical survey. Intensive Care Med 1999;25:567-73.
121. Evans T. International Concensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Organized jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Societe de Reanimation de Langue Francaise, and approved by the ATS Board of Directors, December 2000. Int Care Med 2001;27:166-78.
122. Keenan S, Kernerman P, Cook D, et al. Effect of non-invasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a metaanalysis. Crit Care Med 1997;25:1685-92.
123. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
124. Kramer N, Meyer T, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151:1799-806.
125. Lightowler J, Wedzicha J, Elliott M, et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003;326:185-9.
126. Girault C, Chevron V, Richard J, et al. Physiological effects and optimisation of nasal assist-control ventilation for patients with chronic obstructive pulmonary disease in respiratory failure. Thorax 1997;52:690-6.
127. Meecham Jones D, Paul E, Grahame-Clarke C, et al. Nasal ventilation in acute exacerbations of chronic obstructive pulmonary disease: effect of ventilator mode of arterial blood gas tenions. Thorax 1994;49:1222-4.
128. Vitacca M, Rubini F, Foglio K, et al. Non-invasive modalities of positive pressure ventilation improve the outocme of acute exacerbations in COLD patients. Intensive Care Med 1993;19:450-5.
129. Jolliet P, Tassaux D, Thouret J. Beneficial effects of helium: oxygen versus air: oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med 1999;27:2422-9.
130. Tassaux D, Jolliet P, Roeseler J. Effects of helium-oxygen on intrinsic positive endexpiratory pressure in intubated and mechanicaly ventilated patients with severe chronic obstructive pulmonary disease. Crit Care Med 2000;28:2721-8.
131. DeBoisblanc B, DeBleiux P, Resweber S, et al. Randomized trial of the use of heliox as a driving gas for updraft nebulization of bronchodilators in the emergent treatment of acute exacerbations of chronic obstructive pulmonary disease. Crit Care Med 2000; 28:3177-80.
132. Seemungal T, Donaldson G, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
133. Dewan N, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000;117:662-71.
134. Murata G, Gorby M, Kapsner C, et al. A multivariate model for the prediction of relapse after outpatient treatment of decompensated chronic obstructive pulmonary disease. Arch Intern Med 1992;152:73-7.
135. Seneff M, Wagner D, Wagner R, et al. Hospital and 1-year survival of patients admitted to ICUs with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274:1852-7.
136. Maesen F, Smeets J, Sledsens F, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur J Respir Dis 1995;8:1506-13.
137. Barnes P. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S72-9.
138. White J, Lee J, Young P. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998; 273:10095-8.
139. Feldman M, Taylor P, Paleolog E, et al. Anti-TNFα therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc 1998;30:4126-7.
140. Lundback B, Lindstrom M, Jonsson E, et al. Effect of N-acetylcysteine on the decline of lung function in patients with COPD. Eur J Respir Dis 1995;5(Suppl 15):895.
141. Torphy T, Barnette M, Underwood D, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5.